FDA Determines Regulatory Review Period for BEYFORTUS Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the extension of a patent for a human biological product, submitted by the US Patent and Trademark Office (USPTO).